It’s no secret that one of the biggest hot-button issue right now and in the upcoming election year is high drug costs. The drive to change how drugs are financed and regulated will be front-page news in 2020. You must anticipate how the FDA and other agencies will react and address updates in guidelines, regulations and policies. Get prepared to adapt, plan and prioritize your business processes to conform to the changes.
活动类型: 研讨会
- 开始日期／时间:
- 10 December 2019, 1:30 PM ET
- 结束日期／时间:
- 10 December 2019, 3:00 PM ET
Wayne L. Pines, President, Health Care, of APCO Worldwide, Kevin Madagan, Partner with Reed Smith, John F. Kamp, JD, PhD, Washington Counsel with the Coalition for Healthcare Communication and Tish Eggleston Pahl, Principal at OFW Law will discuss how key regulatory and related issues affecting pharmaceutical quality, regulatory and compliance specialists will be addressed by FDA in 2020:
- The key issues facing the regulation of drugs in 2020, including the status of drug pricing legislation and the regulation of advances in new drug therapies
- The changes we are likely to see, including the evaluation of gene therapies
- FDA’s likely priorities next year, including incentivizing generic drug approvals
- How these changes affect aspects of drug regulation and oversight, including drug applications, FDA reviews, prescribing and drug marketing
- The strategies companies can adopt in anticipation of these changes
Be among the first to gain the information you need to plan for the upcoming industry changes.